Overcoming Barriers In Cell-Based Cancer Therapy

Cell-based cancer therapies, particularly CAR T therapies, have emerged as a significant advancement in recent years. However, widespread adoption has been hampered by challenges related to cost, time, and accessibility. A new approach utilizing “off-the-shelf” therapies derived from modified donor cells is showing promise in overcoming these hurdles.

What is CAR-T Therapy?

CAR-T therapy is a form of immunotherapy where a patient’s immune cells are genetically modified to recognize and destroy cancer cells. Traditionally, this involves extracting cells from the patient, modifying them in a lab, and then reinfusing them. This personalized approach is complex, expensive, and time-consuming, creating manufacturing challenges and long wait times for patients.

Researchers are pursuing two main strategies to address these limitations. One involves directly delivering cancer-targeting instructions to a patient’s immune cells. The other, and the focus of recent advancements, centers on developing universal cell therapies from healthy donors.

Universal Cell Therapies Mean More Accessible Cancer Treatments

A recent report published in The New England Journal of Medicine details a study evaluating a universal approach. Healthy donor T cells were gene-edited to prevent attacks on each other, reduce the likelihood of rejection by the patient’s immune system, and provide resistance to specific drugs. These modified cells were then expanded, frozen, and banked for use in multiple patients.

In the study, 11 patients were treated with cells from a single donor cell bank. All patients achieved remission by day 28, with 9 reaching deep remission, allowing them to proceed to stem-cell transplant. Unfortunately, two patients with residual disease ultimately received palliative care.

Patients experienced expected side effects, including cytokine release syndrome, fever, rashes, prolonged low blood counts, and opportunistic infections, particularly around the time of transplant. While some patients relapsed or died, early follow-up data suggests a substantial proportion remain disease-free after transplant.

Ready-to-Use Cell Therapy Next Steps

The findings demonstrate that universal, gene-edited T-cell therapy can be delivered rapidly and at scale. Ongoing research is focused on improving the durability of the response and reducing the need for intensive conditioning treatments. A single universal donor cell bank could accelerate treatment, lower costs, and improve access to this potentially life-saving therapy.

Frequently Asked Questions

What are allogeneic cells?

Allogeneic cells, also referred to as “allo” meaning “other,” are cells derived from a donor, rather than from the patient themselves. These cells are modified for use in therapies like CAR-T, offering the potential for off-the-shelf availability.

What challenges remain with universal cell therapies?

The primary challenge with universal cell therapies is preventing the donor cells from attacking the patient’s body or being eliminated by the patient’s immune system. Gene-editing is used to address these concerns, but further research is needed to optimize safety and efficacy.

What was the outcome for patients in the recent study?

In the study, 11 patients were treated with cells from a single donor cell bank. All achieved remission by day 28, and 9 reached deep remission, enabling them to proceed to stem-cell transplant. Two patients with residual disease ultimately received palliative care.

As cell-based therapies continue to evolve, how might these advancements reshape the landscape of cancer treatment and patient care?